Differences in Biomarker Expression in GBM Patients with Early Progression After Surgery

Authors:

Joshua Palmer MD, Jianliang Li MD, Lawrence Kenyon MD, David W. Andrews, MD, Lyndon Kim MD, Jon Glass MD, Maria Werner-Wasik MD, Wenyin Shi MD, PhD

Purpose

  • Glioblastoma Multiforme (GBM) is locally aggressive
  • GBM is the most common primary brain tumor in adults
  • Surgery followed by temozolomide and radiotherapy are the standard of care
  • Attempts have been made to increase radiation dose, pursue more aggressive chemotherapy, or add targeted therapy
  • Biomarker expression may help individualize treatment decisions

Download Publication